市場調查報告書
商品編碼
1450839
創傷性腦損傷診斷設備市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍:按技術、設備類型、最終用戶和地理位置Traumatic Brain Injury Diagnostics Equipment Market Size and Forecasts, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technique, Device Type, End User, and Geography |
創傷性腦損傷診斷設備市場規模預計將從2022年的31.57億美元成長到2030年的78.72億美元。對先進診斷設備的加速需求以及對TBI患者快速有效的診斷等因素推動了創傷性腦損傷診斷設備市場成長。然而,造影劑/造影劑的不利影響阻礙了市場的成長。
對先進診斷設備的需求加速推動創傷性腦損傷診斷設備市場的成長
根據醫學研究委員會 2022 年報告,全球每年有 1,000 萬人遭受創傷性腦損傷 (TBI)。同樣,Headway 2024 報告顯示,英國的後天性腦損傷 (ABI) 正在上升; 2019年至2020年,英國共有356,699例因ABI入院登記。其中,男性因頭部受傷入院的人數是女性的1.5倍。根據經濟學人智庫的報告,TBI 每年對全球造成的醫療負擔估計約 4,000 億美元。最常見的 ABI 形式是由事故或中風引起的 TBI。美國疾病管制與預防中心 (CDC) 的報告顯示,美國每年估計有 170 萬人因 TBI 就診、住院和死亡,尤其是 75 歲及以上的成年人,因為他們跌倒的風險很高。由於步態和平衡問題。此外,道路交通事故是美國 TBI 相關死亡的主要原因,並且在 20-24 歲的成年人中發病率最高。因此,製造商正在開發創新產品來診斷 TBI。 2023 年 10 月,生物梅里埃宣布「VIDAS TBI (GFAP, UCH-L1)」獲得歐洲一致性 (CE) 標誌,旨在改善對輕度創傷性腦損傷 (mTBI) 患者的評估。 VIDAS TBI (GFAP, UCH-L1) test measures the concentration of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1)-the two brain biomarkers released into the bloodstream starting from the first hour following a brain受傷.這是一項易於解釋的測試,提供受傷後長達 12 小時的測試窗口,這有助於縮短急診室的總檢查時間。該產品將於 2023 年在部分歐洲、北非和南美市場上市;計劃於 2024 年或 2025 年在全球推出。
用於診斷 TBI 患者的攜帶式非侵入性監測設備的出現是創傷性腦損傷診斷設備市場的未來趨勢
監測組織代謝的新非侵入性方法可以幫助改善腦震盪、中風和 TBI 等腦部疾病的診斷和監測,從而使患者能夠更快地康復。根據 BrainScope 公司白皮書,TBI 的後果導致醫療負擔成本增加,每年達 765 億美元。根據白色報告中揭露的研究結果,在較便宜的護理環境(例如急診室和社區環境(包括緊急護理中心))中安裝「BrainScope One」可能會導致醫療成本顯著降低高達 32.2%紙。 BrainScope One 有助於消除不必要的 CT 掃描,從而降低 TBI 的醫療費用。
此外,來自密西根大學的一組研究人員開發了一種經濟高效、攜帶式、非侵入性的工具——細胞色素 C 氧化酶超連續紅外光譜 (SCISCCO) 系統——來檢測神經元功能障礙。該工具用途極為廣泛,具有多種用途,從作為篩檢腦震盪患者的新設備到在重症監護病房中使用,再到測量患者器官對治療的反應。
同樣,伯明翰大學2024年報告顯示,伯明翰大學的研究人員設計並開發了眼睛安全設備(EyeD)-一種檢測TBI的新型診斷設備。它基於拉曼光譜,這是一種使用智慧型手機相機同時進行眼底成像和光譜分析的光學技術。 EyeD 從視網膜和視神經收集的拉曼光譜有助於使用人工神經網路演算法「SKiNET」作為決策支援工具來分析 TBI 特異性生化變化的存在。 EyeD快速、準確、非侵入性,不會造成額外的不適,並能立即提供有關創傷嚴重程度的資訊,因此非常適合在現場使用——在不幸事件的路邊或運動場上-評估TBI。
創傷性腦損傷診斷設備市場依技術分為非侵入性、侵入性和組合技術。侵入性細分市場在 2022 年佔據最大的市場佔有率。非侵入性細分市場預計在預測期內CAGR最高,達到 12.8%。
創傷性腦損傷診斷設備市場依設備類型分為影像設備和監測設備。成像設備細分市場在 2022 年佔據更大的市場佔有率,預計在預測期內複合CAGR將達到 11.8%。
依最終用戶分類,創傷性腦損傷診斷設備市場分為醫院和診所、診斷中心等。醫院和診所細分市場在 2022 年佔據最大的市場佔有率,預計在預測期內複合CAGR為 12.0%。
根據地理位置,創傷性腦損傷診斷設備市場分為北美、歐洲、亞太地區、南美洲和中美洲以及中東和非洲。 2022年,北美佔據全球最大的腦外傷診斷設備市場。預計亞太地區 2022 年至 2030 年CAGR最高。在北美,美國佔據腦外傷診斷設備市場最大的市場佔有率。美國疾病管制與預防中心 (CDC) 的報告顯示,美國每年估計有 250 萬人患有 TBI。根據 KNAPP & ROBERTS 報告,光是在美國,每 6 名美國人中就有 1 人患有與 TBI 相關的殘疾,約佔 10%。 530萬。隨著 TBI 盛行率的上升,其經濟損失達 765 億美元。 765億美元中,115億美元為直接醫療費用,近650億美元為間接費用。 TBI的主要原因包括跌倒(45%)、機車碰撞(14.3%)、攻擊(10.7%)和不明原因(19.0%)。
競爭格局及重點企業:
GE HealthCare Technologies Inc、Elekta AB、Integra LifeSciences Holdings Corp、Natus Medical Inc、Raumedic AG、BrainScope Co Inc、Luciole Medical AG、Soterix Medical Inc、Medtronic Plc、Vivonics Inc、NanoDx Inc、Compumedics Ltd、Sense Diagnostics Inc、NeuraSignal Inc、NeuraSignal Inc , 和Neurovigil Inc 是創傷性腦損傷診斷設備市場報告中的知名公司。這些公司專注於新技術、升級現有產品和地理擴張,以滿足全球不斷成長的消費者需求。
Sense Neuro Diagnostics 宣布獲準進行出血檢測臨床試驗。 FDA 神經外科、神經介入和神經診斷設備部門批准的這項新試驗於 2023 年 6 月開始,包括來自美國、加拿大和印度 30 個地點的多達 300 名患者。這種非侵入性技術有可能在 2.5 秒內收集 360 個資料點,以檢測腦出血或中風類型,從而幫助醫生、急診人員、神經 ICU 團隊和軍事野戰醫院評估和監測 TBI 做出快速反應。因此,由於美國公司推出創新產品以改善 TBI 患者的診斷結果,創傷性腦損傷診斷設備市場規模可能會激增。
註 - 將為以下提到的地區/國家提供類似的分析
The traumatic brain injury diagnostic equipment market size is expected to grow from US$ 3.157 billion in 2022 to US$ 7.872 billion by 2030. Factors such as the accelerated demand for advanced diagnostic equipment and quick and effective diagnosis for TBI patients propel the traumatic brain injury diagnostics equipment market growth. However, the adverse effects of contrast medium/agent impede the growth of the market.
Accelerated Demand for Advanced Diagnostic Equipment Drives Traumatic Brain Injury Diagnostics Equipment Market Growth
According to the Medical Research Council 2022 report, 10 million people across the world sustain traumatic brain injury (TBI) annually. Likewise, the Headway 2024 report revealed that acquired brain injury (ABI) is rising in the UK; a total of 356,699 hospital admissions were registered due to ABI in the UK from 2019 to 2020. Among these, the male population was 1.5 times higher than females admitted to hospitals for a head injury. As per The Economist Intelligence Unit report, the global healthcare burden of TBI is estimated to be around US$ 400 billion annually. The most common form of ABI is TBI due to an accident or stroke. The Centers for Disease Control and Prevention (CDC) report revealed that an estimated 1.7 million TBI-related emergency department visits, hospitalizations, and deaths occur annually in the US, especially among adults aged 75 years and older as they are at high risk of falling due to problems with gait and balance. Also, road accidents are the leading cause of TBI-related deaths in the US and are highest among adults aged 20-24 years. Therefore, manufacturers are developing innovative products to diagnose TBI. In October 2023, bioMerieux announced Conformite Europeenne (CE) marking for "VIDAS TBI (GFAP, UCH-L1)," a test intended to improve the assessment of patients suffering from mild traumatic brain injury (mTBI). VIDAS TBI (GFAP, UCH-L1) test measures the concentration of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1)-the two brain biomarkers released into the bloodstream starting from the first hour following a brain injury. It is an easy-to-interpret test providing a test window of up to 12 hours after injury, which can help shorten total emergency department workup time. The product's commercial launch was in 2023 for selected European, North African, and South American markets; the global launch is planned in 2024 or 2025.
The emergence of Portable Noninvasive Monitoring Devices to Diagnose TBI Patients Acts as a Future Trend in Traumatic Brain Injury Diagnostics Equipment Market
New noninvasive methods for monitoring tissue metabolism can help improve the diagnosis and monitoring of brain conditions such as concussions, stroke, and TBI, owing to which patients can recover more quickly. The consequences of TBI resulted in increasing healthcare burden costs, accounting for US$ 76.5 billion annually, as per the BrainScope company white paper. The installation of "BrainScope One" in less expensive care settings-e.g., emergency department and community settings (including urgent care centers)-may result in a significant reduction of healthcare costs by up to 32.2%, as per the findings revealed in the white paper. BrainScope One aids in eliminating unnecessary CT scans, thereby reducing healthcare costs for TBI.
Further, a team of researchers from the University of Michigan developed a cost-effective, portable, noninvasive tool-Super-Continuum Infrared Spectroscopy of Cytochrome C-Oxidase (SCISCCO) system-to detect neuronal dysfunction. This tool is extremely versatile, having a range of uses from serving as a new device for screening concussion patients to use in the intensive care unit and gauging patients' organ response to treatment.
Likewise, the University of Birmingham 2024 report revealed that researchers from the University of Birmingham have designed and developed the eye-safe device (EyeD)-a novel diagnostic device to detect TBI. It is based on Raman spectroscopy, an optical technique performed simultaneously on fundus imaging and spectroscopic analysis using a smartphone camera. The Raman spectra collected by EyeD from the retina and optic nerves help in analyzing the presence of TBI-specific biochemical changes using the artificial neural network algorithm "SKiNET" as a decision support tool. EyeD is quick, accurate, and noninvasive, causes no additional discomfort, and provides information on the severity of the trauma instantly, owing to which it is highly suitable while using on-site-at the roadside of the unfortunate event or on the sports pitch-to assess TBI.
The traumatic brain injury diagnostics equipment market is segmented by technique into noninvasive, invasive, and combination techniques. The invasive segment held the largest market share in 2022. The noninvasive segment is anticipated to register the highest CAGR of 12.8% during the forecast period .
The traumatic brain injury diagnostics equipment market, by device type, is bifurcated into imaging devices and monitoring devices. The imaging devices segment held a larger market share in 2022 and is anticipated to register a higher CAGR of 11.8% during the forecast period .
The traumatic brain injury diagnostics equipment market, by end user, is categorized into hospitals & clinics, diagnostic centers, and others. The hospitals & clinics segment held the largest market share in 2022 and is anticipated to register a CAGR of 12.0% during the forecast period .
Based on geography, the traumatic brain injury diagnostic equipment market is segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America accounted for the largest global traumatic brain injury diagnostic equipment market share. Asia Pacific is expected to register the highest CAGR during 2022-2030. In North America, the US accounts for the largest market share of the traumatic brain injury diagnostic equipment market. The Centers for Disease Control and Prevention (CDC) report revealed that an estimated 2.5 million people suffer from TBI annually in the US. According to the KNAPP & ROBERTS report, 1 in every 6 Americans live with TBI-related disability in the US alone, accounting for approx. 5.3 million. With the rising prevalence of TBI, the economic cost accounts for US$ 76.5 billion. Among US$ 76.5 billion, US$ 11.5 billion accounts for direct medical costs and nearly US$ 65 billion for indirect costs. The leading causes of TBI include falls (45%), motor vehicle crashes (14.3%), assaults (10.7%), and unknown (19.0%).
Competitive Landscape and Key Companies:
GE HealthCare Technologies Inc, Elekta AB, Integra LifeSciences Holdings Corp, Natus Medical Inc, Raumedic AG, BrainScope Co Inc, Luciole Medical AG, Soterix Medical Inc, Medtronic Plc, Vivonics Inc, NanoDx Inc, Compumedics Ltd, Sense Diagnostics Inc, NeuraSignal Inc, and Neurovigil Inc are the prominent companies in the traumatic brain injury diagnostic equipment market report. These companies focus on new technologies, upgrading existing products, and geographic expansions to meet the growing consumer demand worldwide.
Sense Neuro Diagnostics announced clearance to conduct clinical trials for hemorrhage detection. The new trial approved by the FDA Division of Neurosurgical, Neurointerventional, and Neurodiagnostic Devices began in June 2023, including up to 300 patients at 30 US, Canada, and Indian sites. This noninvasive technology has the potential to collect 360 data points within 2.5 seconds to detect brain hemorrhage or stroke type, thereby helping quick response by physicians, emergency department personnel, neuro ICU teams, and military field hospitals assessing and monitoring TBI. Therefore, the traumatic brain injury diagnostics equipment market size is likely to surge due to innovative product launches by US-based companies to improve outcomes of diagnosis of patients suffering from TBI.
Note - Similar analysis would be provided for below mentioned regions/countries
Note - Similar information would be provided for below list of companies